Glatiramer Acetate
Treatment for Multiple Sclerosis
Typical Dosage: 20mg subcutaneous daily or 40mg subcutaneous three times a week
Effectiveness
70%
Safety Score
60%
Clinical Trials
108
Participants
2K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
20mg subcutaneous daily or 40mg subcutaneous three times a week
Time to Effect
6-12 months
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
6(Treat 6 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
3(Treat 3 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$65,000
Monitoring:$2,500
Side Effect Mgmt:$200
Total Annual:$67,700
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$120,000/QALY
QALYs Gained
0.6
Outcome-Based Costs
Cost per Responder
$104,153.85
Cost per Remission
$338,500
Glatiramer Acetate Outcomes
for Multiple Sclerosis
Efficacy Outcomes
Overall Effectiveness
+70%
Response Rate
+65%
Remission Rate
+20%
Common Side Effects
Injection site reactions
+40%
Vasodilation (flushing)
+20%
Post-injection reaction (flushing, chest pain, palpitations)
+18%
Rash
+16%
Dyspnea
+14%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
17 completed trials for Glatiramer Acetate in Multiple Sclerosis
Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis
NCT00819195COMPLETED
17 participants
OBSERVATIONAL
San Francisco, United States
Started: Dec 1, 2008
Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis"
NCT03209479COMPLETED
1.33K participants
OBSERVATIONAL
Tokyo, Japan
Started: Nov 24, 2015
Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome
NCT00666224COMPLETEDPHASE3
481 participants
INTERVENTIONAL
Started: Jan 1, 2004
Safety and Effectiveness of Cinnomer® (Glatiramer Acetate) in Multiple Sclerosis (MS) Treatment in Iran
NCT04928313COMPLETED
368 participants
OBSERVATIONAL
Started: Apr 12, 2015
Safety of New Formulation of Glatiramer Acetate
NCT00947752COMPLETEDPHASE3
147 participants
INTERVENTIONAL
Started: Jul 1, 2009
Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness
NCT00203021COMPLETEDPHASE4
208 participants
INTERVENTIONAL
Los Angeles, United States +10 more
Started: Mar 26, 1994
Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate
NCT01569451COMPLETEDPHASE2
53 participants
INTERVENTIONAL
Aurora, United States
Started: Feb 1, 2012
Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients
NCT01167426COMPLETEDPHASE3
148 participants
INTERVENTIONAL
Started: Jul 1, 2010
Efficacy and Safety of GTR in Comparison to Copaxone®
NCT01489254COMPLETEDPHASE3
794 participants
INTERVENTIONAL
Irvine, United States +132 more
Started: Oct 1, 2011
Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)
NCT00937157COMPLETEDNA
12 participants
INTERVENTIONAL
Buffalo, United States
Started: Sep 1, 2007
FOCUS Fatigue Outcome in Copaxone USers
NCT00267319COMPLETEDPHASE4
111 participants
INTERVENTIONAL
Prague, Czechia
Started: Jun 1, 2003
Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®
NCT02499900COMPLETEDPHASE4
861 participants
INTERVENTIONAL
Cullman, United States +96 more
Started: Aug 10, 2015
Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients
NCT03315923COMPLETEDPHASE2, PHASE3
84 participants
INTERVENTIONAL
Isfahan, Iran
Started: Dec 1, 2017
Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).
NCT00337779COMPLETEDPHASE3
1.16K participants
INTERVENTIONAL
Started: Aug 1, 2006
Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis
NCT02753088COMPLETEDPHASE3
158 participants
INTERVENTIONAL
Started: Oct 1, 2013
Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline
NCT00203112COMPLETEDPHASE2
44 participants
INTERVENTIONAL
Started: Jun 1, 2004
A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose
NCT00202982COMPLETEDPHASE2
90 participants
INTERVENTIONAL
La Jolla, United States +19 more
Started: Aug 1, 2003
Showing 20 of 108 total trials